Novo Nordisk A/S
European markets set to open higher amid calls for lower interest rates by Trump
European equity markets are set to open higher on Friday to cap a positive week for stocks. The U.K.’s FTSE 100 is set to open marginally positive, while Germany’s DAX and France’s CAC 40 are expected to open higher by 0.4%, according to FactSet futures data. Meanwhile, the pan-European Stoxx 600 index is expected to […]
Read More
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) on Dec. 5th, 2023. NYSE Group A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I’m back in New York City after spending nearly a […]
Read More
GLP-1s and Brian Thompson’s killing loom large at top health-care conference
Jamie Dimon, chief executive officer of JPMorgan Chase & Co., at the Institute of International Finance (IIF) during the annual meetings of the IMF and World Bank in Washington, DC, US, on Thursday, Oct. 24, 2024. Kent Nishimura | Bloomberg | Getty Images San Francisco, famed for its abundance of hoodie-clad tech workers, was overrun […]
Read More
Stocks making the biggest moves midday: Novo Nordisk, J.B. Hunt, Qorvo and more
Check out the companies making headlines in midday trading. Crypto stocks – Stocks tied to crypto prices jumped amid reports that President-elect Donald Trump could release an executive order making crypto a national priority as soon as the first day of his new term. Shares of crypto exchange operators Coinbase and Robinhood advanced 4.5% and […]
Read More
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
U.S. President Joe Biden speaks about prescription drug costs during an event at NHTI Concord Community College in Concord, New Hampshire, U.S., October 22, 2024. REUTERS/Elizabeth Frantz Elizabeth Frantz | Reuters The Biden administration on Friday unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off […]
Read More
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations. The drugmaker’s […]
Read More
Eli Lilly CEO expects new weight loss pill to be approved next year
David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC Eli Lilly expects its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks told Bloomberg TV on Monday. The company is set to release key late-stage trial data on the drug, orforglipron, by the middle of this year. Eli […]
Read More
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups
Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A few years ago, when Virta Health founder and CEO Sami Inkinen approached employers about leveraging the company’s nutrition-oriented digital diabetes program for obesity-related weight loss, most companies weren’t ready to commit. Now, more employers are all in on nutritional counseling […]
Read More
Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday. That opens the door for broader access to Zepbound, which is […]
Read More
Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to […]
Read More